Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 484 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PD control Clear all
Not listed Phase 2 Interventional

Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR

NCT01364155
View directory record Official record
Conditions
Impaired Glucose Tolerance, Insulin Resistance
Interventions
LIM-0705, Placebo capsules
Drug
Lead sponsor
Limerick BioPharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Oct 27, 2026, 2:23 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

NCT06989840
View directory record Official record
Conditions
Acne
Interventions
TVB-3567, Placebo
Drug
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

FTIH of ECC4703 in Healthy Volunteers

NCT05552274
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
ECC4703, Placebo
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 27, 2026, 2:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Exercise Neuroprotection in Parkinson's Disease

NCT05854524
View directory record Official record
Conditions
Parkinson Disease
Interventions
Aerobic exercise
Procedure
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
30 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Not applicable Interventional Results available

Accelerated Recovery Pathway for Discharge After Surgery in Patients With Pancreatic Cancer

NCT02517268
View directory record Official record
Conditions
Pancreatic Carcinoma
Interventions
Pancreaticoduodenectomy
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1

NCT06204809
View directory record Official record
Conditions
Myotonic Dystrophy 1
Interventions
PGN-EDODM1 for infusion, Placebo
Drug · Other
Lead sponsor
PepGen Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Irvine, California • Palo Alto, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Phase 1 Interventional

Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

NCT05745883
View directory record Official record
Conditions
Chronic Kidney Diseases, Anemia of Chronic Kidney Disease
Interventions
DISC-0974, Placebo
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Los Angeles, California • Lone Tree, Colorado • DeLand, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 27, 2026, 2:23 PM EDT
Recruiting Phase 2 Interventional

RESvEraTrol in Parkinson's Disease (RESET)

NCT07592767
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Trans-Resveratrol
Drug
Lead sponsor
Georgetown University
Other
Eligibility
55 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Phase 4 Interventional Results available

Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine

NCT02403830
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Methylnaltrexone, Placebo, Morphine, Ticagrelor
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 27, 2026, 2:23 PM EDT
Suspended Phase 3 Interventional

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

NCT02546102
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
ICT-107, Placebo
Biological
Lead sponsor
Precision Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Not applicable Interventional Results available

Revitalize Cognition: Near Infrared Stimulation in Parkinson Patients

NCT06688357
View directory record Official record
Conditions
Parkinson Disease
Interventions
Active NIR-PBM (MedX 1116, MCT502), Sham NIR-PBM (MedX 1116, MCT502)
Device
Lead sponsor
University of Florida
Other
Eligibility
62 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Phase 2 Interventional

A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients

NCT02476019
View directory record Official record
Conditions
Obesity
Interventions
ISIS-FGFR4RX, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

NCT02240030
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301 Low Dose, CVT-301 High Dose, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
55
States / cities
Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)

NCT03268941
View directory record Official record
Conditions
Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
Interventions
TAK-906 Maleate, Metaclopramide, TAK-906 Maleate Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Peoria, Arizona • Tucson, Arizona • Little Rock, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Phase 2 Interventional

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

NCT01658501
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea
Drug · Other
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

NCT01971164
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Voice Treatment for Parkinson's Disease

NCT00123084
View directory record Official record
Conditions
Parkinson's Disease, Dysphagia, Dysarthria
Interventions
Voice/Respiration Treatment, Speech/Articulation Treatment
Behavioral
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
45 Years to 85 Years
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2012
U.S. locations
2
States / cities
Denver, Colorado • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Systematic Investigation of Phonetic Complexity Effects on Articulatory Motor Performance in Progressive Dysarthria

NCT03613038
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Parkinson Disease
Interventions
Phonetic complexity effects on speech motor performance
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
19 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Fairway, Kansas • Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

NCT03310021
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet alfa, Apixaban, Rivaroxaban, Edoxaban, Placebo
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 27, 2026, 2:23 PM EDT
Recruiting Not applicable Interventional

Spinal Cord Stimulation for Parkinson's Disease Rehabilitation

NCT06804642
View directory record Official record
Conditions
Parkinson Disease
Interventions
Spinal cord transcutaneous stimulation (scTS)
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease

NCT03178786
View directory record Official record
Conditions
Parkinson Disease
Interventions
PAT sessions
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 27, 2026, 2:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

NCT01454986
View directory record Official record
Conditions
Healthy
Interventions
ALXN1007, Placebo
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 27, 2026, 2:23 PM EDT
Terminated Phase 3 Interventional

Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder

NCT00836069
View directory record Official record
Conditions
Anxiety Disorders
Interventions
No drug name provided by Sponsor; drug referenced as PD 0332334, Paroxetine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 27, 2026, 2:23 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

NCT01536015
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
30 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
26
States / cities
Birmingham, Alabama • Gilbert, Arizona • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 27, 2026, 2:23 PM EDT